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Opposing effects of high- and low-molecular weight
hyaluronan on CXCL12-induced CXCR4 signaling
depend on CD44
K Fuchs1, A Hippe2, A Schmaus1, B Homey2, JP Sleeman1,3 and V Orian-Rousseau*,1
The tumor microenvironment makes a decisive contribution to the development and dissemination of cancer, for example,
through extracellular matrix components such as hyaluronan (HA), and through chemokines that regulate tumor cell behavior
and angiogenesis. Here we report a molecular link between HA, its receptor CD44 and the chemokine CXCL12 in the regulation of
cell motility and angiogenesis. High-molecular-weight HA (hHA) was found to augment CXCL12-induced CXCR4 signaling in both
HepG2iso cells and primary human umbilical vein endothelial cells, as evidenced by enhanced ERK phosphorylation and
increased cell motility. The augmentation of CXCR4 signaling translated into increased vessel sprouting and angiogenesis in
a variety of assays. Small HA oligosaccharides (sHA) efficiently inhibited these effects. Both siRNA-mediated reduction of CD44
expression and antibodies that block the interaction of CD44 with HA provided evidence that CXCL12-induced CXCR4 signaling
depends on the binding of hHA to CD44. Consistently, CD44 and CXCR4 were found to physically interact in the presence of
CXCL12, an interaction that could be inhibited by sHA. These findings provide novel insights into how microenvironmental
components interact with cell surface receptors in multi-component complexes to regulate key aspects of tumor growth and
progression.
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The tumor microenvironment plays a major role in cancer
development and progression, and interactions between
cancer cells and the microenvironment are essential both for
the growth of the primary tumor and for the migration of
metastatic cells to distant organs and their survival there.1
This microenvironment comprises stromal cells such as
angiogenic vascular cells, infiltrating immune cells and
cancer-associated fibroblasts, together with chemokines,
growth factors and other factors released by these and other
cells and a variety of extracellular cellular matrix (ECM)
components.2
A major component of the ECM in the tumor micro-
environment is hyaluronan (HA), a high MW (4106 kDa)
non-sulfated glycosaminoglycan consisting of repeating
subunits of (b,1-4)-D-glucuronic acid-(b,1-3)-N-acetyl-D-
glucosamine.3 Three hyaluronan synthase (HAS) enzymes
are involved in the production of HA (HAS1–3), whereas HA
degradation is controlled by hyaluronidases (HYALs),
six of which have been identified.4 Overproduction of HA in
tumors such as breast, colorectal, prostate, lung, ovarian
and gastric cancers correlates in several cases with
malignant progression and poor survival,5–9 as does high
expression of HAS and low expression of HYALs.10
However, overexpression of HYALs can also correlate with
malignancy7,10–14 and accumulation of HA can decrease
tumorigenic potential.15–18 These contradictory observations
can be reconciled by the observation that the concurrent
expression of synthesizing and degrading enzymes has the
strongest impact on tumor growth and metastasis,15,16,19
suggesting that increased synthesis coupled to turnover of HA
is decisive in this context.
Enhanced synthesis and turnover of HA can result in the
local accumulation of small HA oligosaccharides (sHA).
sHA has stimulatory effects on a number of biological
processes that are not observed with high-molecular-
weight HA (hHA). For example, angiogenesis, a key
component of tumor growth and progression, can be
triggered by sHA through the stimulation of endothelial cell
(EC) proliferation, motility and tubule formation (reviewed in
Toole10). Surprisingly, however, administration of sHA to
several types of tumor xenografts inhibited rather than
stimulated tumor growth.20,21 These discrepancies might
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suggest a context-dependent response to HA, influenced
by the local environment.
The CD44 family of transmembrane glycoproteins is a
major class of cell surface receptors for HA that controls
differentiation, proliferation, survival and migration of cells,
and thereby has an important role in tumor progression and
metastasis.22 Ample evidence also implicate CD44 in the
regulation of angiogenesis. In vitro, a CD44 antibody blocked
EC proliferation and tube formation.23 Consistently, vascu-
larization of matrigel implants and tumor and wound
angiogenesis were drastically reduced in CD44-knockout
mice.24 Furthermore, the CD44v6 isoform on ECs collabo-
rates with vascular endothelial growth factor 2 (VEGFR-2), a
central regulator of angiogenesis, and thereby fosters
activation of VEGFR-2. The ectodomain of CD44v6 is
required for the activation process, and the cytoplasmic
domain controls signaling from VEGFR-2.25 Accordingly,
tumor angiogenesis was blocked by a CD44v6 peptide in this
study.
Other components of the tumor microenvironment that
induce angiogenesis are the chemokine CXCL12 (SDF-1a)
and its receptor CXCR4. CXCL12 stimulates angiogenesis
directly by acting on ECs, as they express CXCR4 (reviewed
in Salcedo and Oppenheim26). CXCL12 is also involved in
other aspects of vascular remodeling, for example, by
attracting bone marrow-derived CXCR4-positive endothelial
progenitor cells (EPCs) to the sites of vessel injury.27 This
latter role for CXCR4 and its ligand in directing the ‘homing’ of
cells to particular organ microenvironments is also important
for the migration to and the settlement and retention of
hematopoietic stem cells (HSCs) in the bone marrow.28 Also
during metastatic dissemination, CXCR4-expressing meta-
static cells home to organs that express CXCL12 (reviewed in
Burger and Kipps29).
The migration of HSCs to the bone marrow is also
dependent on HA/CD44 interactions.28 HA is highly
expressed in sinusoidal endothelium and in the endosteum,
a region adjacent to the bone, where primitive HSCs are
present. Blocking CD44–HA interaction prevents the settle-
ment of HSCs in these regions. Furthermore, the migration of
leukemic stem cells to the bone marrow niche requires both
CD44 and CXCR4/CXCL12, as antibodies against either
CXCR4 or CD44 can block this migration.30
Prompted by the similarities between the effects of
CXCR4/CXCL12 signaling and HA/CD44 interactions in a
variety of settings, in this study we discovered a regulatory
interplay betweenCD44, HA, CXCR4 andCXCL12 operating
in both tumor cells and ECs. We show that the activation of
CXCR4 by CXCL12 is increased upon preincubation of cells
with hHA. In stark contrast, sHA fragments block CXCL12
signaling. The effects of HA on CXCR4 signaling are
dependent on CD44. A complex formed between CXCR4
and CD44 in the presence of CXCL12 was abrogated by
preincubation with sHA. Vessel sprouting and aortic ring
assays in vitro, as well as matrigel plug assays in vivo
demonstrate a dependence of CXCL12/CXCR4 signaling on
HA and CD44 in angiogenesis. Together these data reveal a
novel mechanism through which HA in the microenviron-
ment can influence tumor cell behavior and regulate
angiogenesis.
Results
Opposing effects of hHA and sHA on CXCR4-induced
signaling and cell motility. Possible effects of HA on
CXCL12-induced signaling were examined using the
CXCR4-positive hepatoma cell line HepG2iso31 and primary
human ECs (HUVECs). Both cell types express CXCR4
(Figure 1a) and the major HA receptor CD44. Hermes 3, an
antibody that recognizes all CD44 isoforms, detected several
bands in HepG2iso cells and HUVECs. The major band
corresponds to CD44s, the smallest ubiquitously expressed
CD44 isoform (reviewed in Orian-Rousseau32). The upper
bands correspond to other CD44 isoforms expressed at lower
levels. HepG2 cells that do not express any CD44 isoform
served as a negative control (Figure 1a and Olaku et al.33).
hHA and sHA have been reported to exert differing effects
on tumor growth, angiogenesis and inflammation. We therefore
examined the effect of hHA and sHA of 6–10 disaccharides in
length on CXCL12-induced signaling using phosphorylation
of Erk as a read-out (Figure 1b). HepG2iso cells were
induced with CXCL12 alone or incubated with increasing
amounts of hHA before induction with CXCL12. CXCL12 alone
induced Erk phosphorylation. In comparison, hHA treatments at
concentrations ranging from 50 to 400mg/ml further augmented
CXCL12-induced Erk phosphorylation. The effect of hHA was
best seen at 400mg/ml, a concentration used for further
experiments. In HUVECs, CXCL12 also induced Erk phosphor-
ylation, a response that was further enhanced by preincubation
with 400mg/ml hHA. In stark contrast, sHA decreased
CXCL12-induced Erk phosphorylation in both HepG2iso cells
and HUVECs, with pronounced inhibition at 1mg/ml (Figure 1b).
Note that given the difference in molecular weight between
hHA and sHA, a concentration of 1mg/ml sHA equates
approximately to 400mg/ml hHA at the molar level.
To investigate whether the effects observed with hHA were
due to an activation of the Gai subunit, a G protein involved in
CXCR4 signaling (reviewed in Teicher and Fricker34), we
repeated the previous experiment in the presence or the
absence of pertussis toxin (PTX), a specific inhibitor of this
subunit.35 The effects of hHA on CXCL12-induced Erk
phosphorylation were completely abrogated by this drug
(Figure 1c), indicating that the action of hHA is mediated
through the Gai-induced Erk pathway.
The effects of hHA and sHA on CXCR4 signaling were
further examined using in vitro monolayer wound closure
assays. A wound of defined size was generated in confluent
monolayers of HepG2iso cells. Migration of cells to fill the
wound upon induction with CXCL12 alone strongly and
significantly increased wound closure after 24 h (Figure 1d).
This effect was potently augmented by preincubation with
hHA in a statistically significant manner. Preincubation with
hHA or sHA alone had no effect on wound closure compared
with non-treated control cells. Consistent with the inhibitory
effect of sHA on CXCL12-induced Erk phosphorylation,
preincubation with sHA completely inhibited the augmented
wound closure in response to CXCL12 (Figure 1d).
Similar experiments were performed with HUVECs.
Spontaneous wound closure was faster than that observed
with HepG2iso cells. Nevertheless, a statistically significant
increased wound closure in the presence of CXCL12 was
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observed after 24 h, which was further and significantly
augmented by preincubation with hHA. In addition, sHA
inhibited CXCL12-induced migration (Figure 1d). Proliferation
assays revealed that CXCL12 did not induce proliferation
of either HepG2iso cells or HUVECs to any significant
extent during the time period of the wound closure assay
(data not shown), ruling out thatCXCL12 and hHAmight induce
monolayer wound closure by promoting cell proliferation.
Opposing effects of hHA and sHA on CXCR4 activity in
angiogenesis assays in vitro. CXCR4/CXCL12 mediates
angiogenesis, vascular remodeling and regeneration by
Figure 1 HA modulates CXCL12 signaling and migration. (a) Expression of CD44 and CXCR4 in HepG2, HepG2iso cells and HUVECs was evaluated by western blot
analysis using a panCD44-specific antibody (Hermes 3) and a CXCR4-specific antibody (ab2074). The apparent molecular weights are indicated. (b) CXCL12-induced Erk
phosphorylation was evaluated using a phospho-Erk-specific antibody to probe western blots of lysates from HepG2iso cells and HUVECs treated with the indicated
compounds. Erk staining was used as loading control. Where indicated, the cells were preincubated with increasing concentrations of high-molecular-weight HA (hHA) or small
HA oligosaccharides of 6–10 disaccharides in length (sHA). A similar experiment was performed with HUVECs using 400mg/ml hHA and 1mg/ml sHA. These concentrations
were used in all subsequent experiments. The numbers between the Erk and phospho-Erk panels indicate fold induction. (c) CXCL12-induced phosphorylation of Erk in
HepG2iso cells in the absence or presence of hHA and PTX as indicated. The toxin was applied to the cells at 500 ng/ml, 10 min before induction with CXCL12. (d) Monolayer
wound assays performed with HepG2iso cells and HUVECs in the presence or absence of CXCL12, hHA and sHA as indicated. The upper panel shows representative images
of wound closure after 24 h under the indicated conditions using a Canon Power Shot S620 digital camera connected to an Axiovert 40c Zeiss microscope ( 10 objective).
The black lines indicate the wound border immediately after monolayer wounding. The lower panels show quantification of the wound closure using the computer program
ImageJ (NIH). Experimental data are reported as mean±S.D. of five independent experiments (*Po0.05; **Po0.01; ***Po0.005; Student’s t-test)
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inducing the recruitment of EPCs to existing vessels or by
acting directly on ECs (reviewed in Ho et al.36). In order to
examine the contribution of HA in CXCL12-dependent
angiogenesis in vitro, we performed a fibrin bead sprouting
assay using HUVECs (Figure 2a). The length of vessel-like
structures built by ECs attached to the beads was signifi-
cantly enhanced by treatment with CXCL12, and was further
increased in a statistically significant manner by treatment
with CXCL12 and hHA together (Figure 2a). In contrast, sHA
totally blocked the enhanced sprouting induced by CXCL12,
whereas hHA and sHA had no effect on sprouting in the
absence of CXCL12 (Figure 2a).
The effect of sHA on CXCL12-induced sprouting was
further analyzed using aortic ring assays (Figure 2b).
Sprouting from aortic rings requires proliferation, migration
of ECs, tube formation, branching and pericyte recruitment,
and therefore provides a relevant measure of angiogenesis
ex vivo. Aorta from C57BL/6 mice were isolated, cut into
pieces and embedded in collagen gels. CXCL12 significantly
enhanced the outgrowth of blood vessels from aortic rings
after 9 days of culture, an effect that was completely inhibited
by concomitant treatment with sHA (Figure 2b). Note that the
high viscosity of hHA and collagen admixes did not allow
aortic ring assays to be performed in the presence of hHA.
CD44 mediates the effect of HA on CXCL12-induced
signaling. CD44, the principal HA receptor,37 can bind to
sHA fragments with a minimum size of six HA residues
corresponding to three disaccharide subunits.38 To investigate
whether CD44 mediates the effects of HA on the
CXCL12-CXCR4 pathway, we repressed expression of all
CD44 isoforms in HepG2iso cells using siRNA, then
measured the induction of Erk phosphorylation upon
CXCL12 treatment either alone or together with hHA
(Figure 3a). In control siRNA-transfected cells, Erk
phosphorylation was induced upon CXCL12 treatment, a
response that was further increased upon preincubation with
hHA before CXCL12 treatment, as expected from the data in
Figure 1. Repression of CD44 expression dramatically
decreased the effect of hHA on CXCL12-induced Erk
phosphorylation, suggesting that CD44 mediates the ability
of hHA to augment CXCR4 signaling. Repression of CD44
Figure 2 HA modulates CXCL12-induced angiogenesis. (a) Sprouting of HUVECs seeded on beads and embedded in fibrinogen in the presence of CXCL12, hHA and
sHA as indicated. Left panel: representative pictures were taken with an Olympus IX81 confocal microscope ( 2 objective) after 10 days of culture. Right panel: quantification
of sprouting from eight independent experiments (mean±S.D.) assessed by evaluating the total vessel length per bead using the computer program ImageJ. (b) Vessel
outgrowth from mouse-derived aorta-pieces treated with CXCL12 and sHA as indicated. Pictures were taken on day 10 using a Canon Power Shot S620 digital camera
connected to an Axiovert 40c Zeiss microscope ( 5 objective). Quantification was carried out by counting the number of vessels that grew out. Data were analyzed using
ImageJ. Experimental data are reported as mean±S.D. of five independent experiments. Each data point represent the outgrowth from 15 aorta pieces taken from five mice
(**Po0.01; ***Po0.005; Student’s t-test)
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expression also attenuated the ability of CXCL12 to induce
Erk phosphorylation in the absence of exogenously added
hHA (Figure 3a). As HepG2iso cells clearly synthesize HA
(Figure 3b), this suggests that CXCL12-induced CXCR4
signaling is also regulated by CD44 through the action of
endogenously produced HA.
To further demonstrate an involvement of CD44 in the
HA-mediated regulation of CXCR4 signaling, we performed a
chemotaxis assay using ibidi chambers to assess directed
migration of HepG2iso cells toward a CXCL12 gradient
(Figure 3c). In the absence of CXCL12, the motility of the
cells was very low. CXCL12 acted as a chemoattractant for
Figure 3 CD44 is required for hHA-modulated CXCL12 signaling and directional migration. (a) HepG2iso cells were transiently transfected with panCD44 siRNA (CD44
siRNA) or control siRNA (ctrl siRNA) as indicated. Erk phosphorylation upon treatment of the cells with CXCL12 and/or hHA as indicated as well as total Erk levels were
determined using western blot analysis. (b) HA staining (green fluorescence) of serum-starved HepG2iso cells and HUVECs was performed using a biotinylated HA-binding
protein (aHA). Nuclei were counterstained with DAPI (blue fluorescence). Images were taken with a SpE confocal microscope (Leica,  63 magnification). As a control, cells
were pretreated with hyaluronidase (HAase) before staining (right panel). (c) Upper panel: representative trajectories of HepG2iso cells cultured inside an IBIDI m chemotaxis
chamber containing CXCL12 (200 ng/ml) or PBS as a control. Cell were transfected either with 5 nM CD44-specific siRNA (CD44 siRNA) or control siRNA (ctrl siRNA) as
indicated. Lower panel: statistical analysis of the HepG2iso cell trajectories in three independent experiments (mean±S.D.): average DY, mean net distance (RU) traveled
along the chemokine gradient (y axis). DY/IDXIo 1, percentages of HepG2iso cells traveling a longer distance in the direction of chemokine gradients (y axis) than in the
direction orthogonal to the gradients (x axis) (*Pr0.05; Student’s t-test). Migration of the cells is observed for 60 h with a Zeiss Cell Observer. Data were analyzed using
ImageJ. (d) Representative example of monolayer wound assays performed with HepG2iso cells transiently transfected with panCD44 siRNA (CD44 siRNA) or control siRNA
(ctrl siRNA). The cells were treated with CXCL12 and hHA as indicated. Left panel: representative pictures taken 24 h after monolayer wounding using a Canon Power Shot
S620 digital camera connected to an Axiovert 40c Zeiss microscope ( 5 objective). The black lines indicate the wound border immediately after monolayer wounding.
Quantification of wound closure from six independent experiments using the computer program ImageJ is shown in the right panel. The error bars represent the mean±S.D.
(*Po0.05; **Po0.01; ***Po0.005; Student’s t-test)
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the HepG2iso cells, but this effect was abrogated by siRNA-
mediated downregulation of CD44 expression (Figure 3c).
Monolayer wound assayswere also performedwith HepG2iso
cells (Figure 3d). As expected from Figure 1, CXCL12
significantly increased wound closure in control siRNA-
transfected cells, an effect that was further significantly
augmented by concomitant incubation with hHA. However,
in HepG2iso cells depleted for CD44, neither CXCL12 alone
nor in combination with HA induced migration of cells and
wound closure over and above that observed in non-treated
cells (Figure 3d).
To further substantiate the notion that binding of hHA to
CD44 is required for CXCL12-induced CXCR4 signaling, we
used the BU52 antibody that blocks the binding of HA to
CD44. In the presence of BU52, CXCL12-induced Erk
phosphorylation in HepG2iso cells was drastically reduced
(Figure 4a). No inhibition was observed in the presence of an
IgG control. This effect is specific to CXCL12-induced
signaling, as transforming growth factor a (TGFa)-induced
Erk activation was not affected by the BU52 antibody. The
migration of HepG2iso cells and HUVECs was also measured
in the presence or absence of the BU52 antibody using
monolayer wound closure assays. For both cell types, BU52
completely abrogated migration in response to CXCL12 or
CXCL12 and hHA, whereas an IgG control antibody had no
effect (Figures 4b and c). Thus, the binding of CD44 to HA is
necessary for CXCL12-induced CXCR4 signaling. The
migration observed in the presence of CXCL12 alone might
be due to the endogenous HA production by HUVECs
(Figure 3b).
The role of CD44 in CXCL12-induced angiogenesis was
examined in aortic ring assays. The anti-murine CD44
antibody KM81 that inhibits the binding of HA to CD4439
completely abrogated the ability of CXCL12 to induce vessel
sprouting in a statistically significant manner (Figure 5a).
These data indicate that the effects of HA on CXCL12-
induced CXCR4 signaling are mediated by CD44. We
therefore tested whether CXCR4 and CD44 can physically
associate. Indeed, CD44 was detected in lysates of HepG2iso
cells and HUVECs immunoprecipitated with an anti-CXCR4
antibody (Figure 5b). In similar experiments, CXCR4 was
detected in immunoprecipitates of CD44. The association
between CXCR4 and CD44 was dependent on the presence
of CXCL12 (Figure 5b). Importantly, formation of the
Figure 4 Binding of HA to CD44 is required for CXCL12 signaling. (a) Erk phosphorylation induced by CXCL12 or TGFa in HepG2iso cells in the presence or absence of
the BU52 antibody (aCD44) that blocks HA binding by CD44 was evaluated using western blot analysis. IgG served as a negative control. Total Erk levels served as a loading
control. The numbers between the Erk and phospho-Erk panels indicate fold induction of Erk phosphorylation. (b and c) Monolayer wound assays using confluent monolayers
of HepG2iso cells (b) and HUVECs (c) in the presence of CXCL12, hHA, the BU52 antibody (aCD44) or an IgG control as indicated. The left panels show representative
pictures taken 24 h after monolayer wounding using a Canon Power Shot S620 digital camera connected to an Axiovert 40c Zeiss microscope ( 10 objective). The black
lines indicate the wound border immediately after monolayer wounding. Experimental data are reported as mean±S.D. of three independent experiments shown in the right
panels (*Po0.05; **Po0.01; ***Po0.005; Student’s t-test)
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CXCR4–CD44 complex was inhibited by preincubation with
sHA. These results suggest that sHA exerts its inhibitory
effects by preventing the formation of a complex between
CD44 and CXCR4 in the presence of CXCL12. Conversely,
these data also suggest that hHA fosters complex formation
betweenCXCL12, CD44 andCXCR4, and that this complex is
required for downstream signaling to Erk.
Activation of CXCL12-dependent signaling by hHA
drives angiogenesis in vivo. The role of HA and CD44 in
CXCL12-induced angiogenesis in vivo was examined using a
mouse angiogenesis assay in which the ingrowth of vessels
into a subcutaneous matrigel plug is evaluated. CXCL12
either alone or in combination with sHA or hHA was mixed
with matrigel and then injected into the flanks of C57/BL6
mice (Figure 6a). Each animal was injected with a control
matrigel plug on one flank and a plug containing CXCL12
alone or in combination with hHA or sHA on the other side.
Vascularization of the matrigel plugs after 3 weeks in the
mice was evaluated by quantifying blood vessels in sections
of the plugs using CD31 immunostaining (Figure 6a).
As expected, CXCL12 was able to significantly enhance
vascularization of the matrigel plugs, an effect that was
further significantly augmented in matrigel plugs containing a
mixture of hHA and CXCL12. In contrast, only few blood
vessels were detected in the presence of sHA, comparable to
the number observed in the absence of growth factor
addition. The same experiment was performed in the
presence of the KM81 antibody that prevents the binding of
HA to CD44 (Figure 6b). This antibody dramatically and
Figure 5 Binding of HA to CD44 is required for CXCL12-induced vessel formation. (a) Mouse-derived aorta pieces embedded in collagen were treated with CXCL12 and
KM81 CD44 antibodies that block HA binding to CD44 (aCD44) or with IgG as indicated. The left panel shows representative pictures of vessel outgrowth taken after 10 days
using a Canon Power Shot S620 digital camera connected to an Axiovert 40c Zeiss microscope and evaluated using ImageJ. The right panel shows quantification of vessel
outgrowth. Experimental data are reported as mean±S.D. of four independent experiments. Each data point represents 11 aorta pieces from four independent mice.
(***Po0.005; Student’s t-test). (b) Coimmunoprecipitation of CD44 and CXCR4 using lysates from HepG2iso cells (left panels) and HUVECs (right panels) that had been
treated with CXCL12 and sHA as indicated. In each case, the samples in the two upper panels were immunoprecipitated with CXCR4 antibodies (IP CXCR4), and the samples
in the two lower panels were immunoprecipitated with CD44 antibodies (IP CD44). The western blots were probed with either CD44 or CXCR4 antibodies as indicated between
the left and right panels. Negative control immunoprecipitations were performed using IgG. The lanes labeled ‘Input’ contain a sample of the lysate that was used for the
immunoprecipitations. Where indicated, western blots were exposed for longer times to reveal weak signals
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significantly blocked the formation of blood vessels in the
matrigel plugs as compared with an IgG control. These
in vivo data validate the role of HA and CD44 in regulating
CXCL12-dependent angiogenesis.
Discussion
In this paper, we show that hHA promotes CXCL12-induced
CXCR4 activation, whereas sHA fragments of 6–10 disac-
charides in length inhibit CXCR4-induced Erk phosphorylation.
These opposing effects were also observed in the
CXCL12-induced angiogenesis in both ex vivo and in vivo
assays. hHA fosters CXCR4 signaling through CD44,
because both knockdown of CD44 and the blocking of HA
binding to CD44 inhibited augmentation of CXCL12-induced
signaling and migration in response to hHA. The inhibition of
complex formation between CD44 and CXCR4 by sHA
suggests that the inhibitory effects of sHA are also mediated
through CD44.
Our findings have significance for a broad range of
physiological and pathological processes involving CXCR4
signaling. In the context of cancer, hHA-augmented CXCR4
signaling could promote tumor cell dissemination by enhancing
the motility of CXCR4-positive tumor cells. Furthermore,
through promoting angiogenesis, hHA-augmented CXCR4
signaling might foster the growth of tumors and their
metastatic spread. The collaboration between CD44, HA,
CXCL12 and CXCR4 might also be important for the
establishment of a niche for metastatic cells in distant
organs. In line with this notion, an HA matrix produced by
Figure 6 Formation of blood vessels in vivo is induced by CXCL12 and can be modulated by HA. (a) CXCL12, hHA and sHA as indicated were mixed with matrigel and
injected subcutaneously into mice. Vascularization of the plugs after 21 days in the mice was evaluated by sectioning the plugs and staining them with anti-CD31 antibodies
(red fluorescence). The sections were also counterstained with DAPI (blue fluorescence) to label cell nuclei. The upper panels show representative pictures of the stained plug
sections. Images were taken using a Leica DM5500 microscope ( 20 objective). The number of CD31-positive vessels in the plugs per mm2 was then evaluated. The scale
bar represents 75mm. The lower panel shows quantification of the data, with each data point representing the mean number of vessels per mm2 from five independent plugs.
(b) Matrigel plug assays identical to those in a were performed, except that the matrigel was mixed with CXCL12, the CD44 antibody KM81 or an IgG control as indicated.
Representative pictures of stained plug sections (left panel) and vessel quantification (right panel) as described for a are shown. Experimental data are reported as
mean±S.D. of five independent plugs. (*Po0.05; **Po0.01; ***Po0.005; Student’s t-test)
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CD44v6-positivemetastatic tumor cells supports their migration
and enhances their resistance to apoptosis.40 In addition, the
survival of metastatic cells in distant organs is inhibited by
blocking CD44v6, as a CD44v6 peptide that inhibits the
coreceptor function of CD44v6 for the receptor tyrosine kinase
(RTK) Met eliminates established metastases in the lungs (our
own unpublished data). The survival of metastatic cells in the
lungs might rely both on the CD44v6-dependent Met signaling
as well as on CXCR4 signaling augmented by CD44 and hHA.
Enhanced angiogenesis through augmented CXCR4 sig-
naling mediated by CD44 and hHA is not only relevant in the
tumor context but also in other situations in which CXCR4
promotes vessel growth and repair. CXCL12 can act directly
on EC to induce angiogenesis (reviewed in Salcedo and
Oppenheim26). Although the CXCL12-CXCR4 effect on tumor
angiogenesis has been reported to be independent on
VEGF,41 other studies suggest that CXCR4 signaling leads
to increased release of VEGF from ECs. In turn, VEGF fosters
both CXCR4 and CXCL12 expression in ECs, leading to
amplified angiogenic signaling (reviewed in Salcedo and
Oppenheim26). CXCL12-induced CXCR4 signaling is also
involved in the recruitment of EPCs to sites of arterial injury,
where they participate in regenerative re-endothelialization,42
a step where CD44 and hHA may be relevant.
Our data also cast light on how CXCR4 regulates homing of
cells to particular sites. In particular, the data presented here
give amechanistic insight into howCD44 and HA contribute to
the settlement of HSCs and leukemic stem cells in the bone
marrow niche, as in both cases blocking of CD44 impaired the
CXCL12-induced homing of cells to their niche.28,30 Similarly,
migration of bone marrow cells (BMCs) to sites of myocardial
infarction can be induced by incorporation of CXCL12 into HA
hydrogels implanted into the infarction sites.43 Consistent with
our observations, this study found that the sustained release
of CXCL12 together with HA drastically increased the number
of BMCs at the infarction site as compared with the use of
CXCL12 alone, leading to increased formation of new blood
vessels and improved repair of the damaged organs.
Our data clearly show that CXCR4 and CD44 form a
physical complex in a CXCL12-dependent manner. In this
complex, hHA could conceivably act in a number of ways to
promote CXCR4 signaling. For example, it could induce or
stabilize the complex between CXCR4 and CD44, perhaps by
inducing clustering of CD44 that might structure the complex.
Indeed, FRET analysis has shown that hHA can induce CD44
clustering at the cell surface, an event that is strongly
attenuated by addition of sHA.44 Our observation that sHA
interferes with CXCR4 signaling would be consistent with the
notion that hHA serves to cluster CD44, thereby fostering
complex formation between CD44, CXCR4 and CXCL12.
Alternatively or in addition, direct binding of CXCL12 to hHA
might explain the influence of HA on CXCR4 signaling, for
example, by concentrating CXCL12 in the vicinity of CXCR4.
The binding of chemokines to glycosaminoglycans occurs
through negative charges present on glycosaminoglycans
such as HA that can interact with the positively charged
chemokines.45 Consistent with this notion, the direct binding
of HA macromers to CXCL12 has recently been demon-
strated.43 In this scenario, CD44 would promote CXCL12-
induced CXCR4 signaling by tethering hHA complexed with
CXCL12 in the close vicinity of CXCR4, thereby fostering the
interaction between CXCR4 and its ligand. In contrast, sHA
would saturate CD44–HA-binding sites non-productively, as
its short length would permit binding to CD44 but not
concomitant binding to CXCL12.
An anti-angiogenic action for hHA and a pro-angiogenic
effect for sHA have been reported.46 On the other hand, our
data suggest that hHA should promote angiogenesis and
tumor growth, whereas sHA would have an inhibitory effect.
Injection of sHA oligomers into tumor-bearing animals inhibits
tumor growth,21 and at least one of the several HYAL genes
that contributes to sHA production corresponds to a pre-
viously mapped tumor suppressor gene,47 possibly consistent
with our findings. Moreover, the effects of HA and sHA are
likely to be context dependent, particularly with regard to the
spectrum of growth factors and chemokines found in a
particular microenvironment. Indeed, we have observed
opposite effects to the ones described here for hHA and
sHA in the case of the RTK Met. In this case, hHA inhibits Met
activation, whereas sHA promotes it (our own unpublished
results). Differences in the mode of activation of RTKs
compared with G-Protein-coupled receptors such as CXCR4
might therefore also contribute to differences in the biological
activity of hHA and sHA.
In summary, our data uncover a novel regulatory network
through which HA of different sizes has contrasting effects
on CXCL12-induced CXCR4 signaling in a CD44-dependent
manner. This network provides a framework that
allows context-dependent regulation of cell motility and
angiogenesis.
Materials and Methods
Cells. Human umbilical vein ECs (HUVECs; Provitro GmbH, Berlin, Germany)
were grown in Endothelial Cell Growth medium supplemented with EGM-2
SingleQuot Kit Supplements and Growth Factors (Lonza GmbH, Basel,
Switzerland). ECs were used at less than 10 passages. The human
liver carcinoma cell lines HepG2 (ATCC) and HepG2iso31 were grown in
DMEM (Invitrogen, Darmstadt, Germany) supplemented with 10% FCS
(PAA Laboratories, Coelbe, Germany).
Reagents. The antibodies used in this study were directed against human
CD44 (Hermes 3, gift from S Jalkannen, Turku, Finland) and BU52 (Pierce,
Rockford, IL, USA)), mouse CD44 (KM81 from ATCC), human CXCR4 (ab2074
from Abcam, Cambridge, UK), Erk (K-23 from Santa Cruz Biotechnology, Dallas,
TX, USA) and Erk phospho-p44/42 (Cell Signaling Technology, Boston, MA,
USA). The horseradish peroxidase-coupled secondary antibodies were from Dako
(Hamburg, Germany), the murine and human CXCL12 and the human TGFa from
R&D Systems (Wiesbaden, Germany). Hepatocyte growth factor was a generous
gift of George Vande Woude (Van Andel Institute). Healon was from
Abbott Medical Optics (Santa Ana, CA, USA). Small HA oligosaccharides
(6–10 disaccharides) were prepared as previously described.48
siRNA oligonucleotides and transfection. Aliquots of cells (1 105)
were seeded in 12-well plates and transfected with 5 nM CD44 pan siRNA
(SI00012775; SI03037419; SI03062661; Qiagen, Hilden, Germany) or control
siRNA (50-UAAUGUAUUGGAACGCAUAUU-30; 50-AGGUAGUGUAAUCGCCUUG
UU-30 and 50-UGCGCUAGGCCUCGGUUGCUU-30; Eurofins MWG GmbH,
Ebersberg, Germany) using Lipofectamine 2000 (Invitrogen), according to the
manufacturer’s protocol.
Activation of Erk. Cells were serum-starved for 24 h, then induced with the
indicated growth factors (20 ng/ml) for 10 min at 37 1C. Where indicated, the cells
were treated with BU52 (3mg/ml), hHA (400mg/ml) or sHA (6–10 disaccharides,
1 mg/ml) at 37 1C for 30 min before induction, unless otherwise stated. Activated
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Erk was determined and quantified using western blot analysis as previously
described.25
HA detection. Cells were seeded in 12-well plates on cover slips (2.5 105
cells per well) and starved for 24 h. Paraffin sections were stained overnight with
biotinylated HA-binding protein (HABP (Merck, Darmstadt, Germany), 2.5mg/ml).
After incubation with Streptavidin/HRP (Invitrogen) for 45 min, nuclei were stained
with DAPI (Dako). For controls, cells were incubated with 50 U/ml hyaluronidase
(Bovine Testis Hyaluronidase, Sigma, Munich, Germany) before fixation.
Coimmunoprecipitation. HUVECs or HepG2iso cells (1.5 106 in 10-cm
plates) were stimulated with the indicated ligands. For immunoprecipitation (IP)
of CD44, cells were lysed in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1% Triton-X-100, 0.1% SDS, 1% sodium deoxycholate, 1 mM sodium
orthovanadate, 1 mM aprotinin and 1 mM leupeptin. The lysis buffer for the
CXCR4 IP was: 0.1% Brij 58, 150 mM NaCl, 20 mM Tris-HCl (pH 8.2), 2 mM
EDTA, 1 mM sodium orthovanadate, 1 mM aprotinin and 1 mM leupeptin. Cells
were lysed for 30 min on ice, then centrifuged for 20 min at 12 000 g. The
cleared lysates were incubated with antibody-coated protein A/G agarose
beads (Merck). The beads were washed in lysis buffer, then subjected to
western blot analysis.
Monolayer wounding assay. Cells were seeded in 12-well plates
(2.5 105 cells per well). A scratch (monolayer wound) was made in the
confluent cell layer 24 h later with a sterile pipette tip. Fresh medium containing
400mg/ml Healon, 1 mg/ml sHA or 3 mg/ml BU52 was added as indicated. After
10 min at 37 1C, induction with CXCL12 (20 ng/ml) was performed where
indicated.
Chemotactic cell migration. Chemotactic cell migration assays were
performed with collagen-coated chemotaxis m-slides (Ibidi, Martinsried, Germany)
according to the manufacturer’s protocol. HepG2iso cells (1 106 cells/ml) were
seeded onto the slides and 24 h later gradients (10–200 ng/ml) were generated
with recombinant CXCL12.
Fibrin bead assay. The assay was performed as described previously,49
except that CXCL12 and/or HA were used as indicated. Pictures were taken with
an Olympus IX81 confocal microscope ( 2 objective). A detailed protocol is
available on request. The number of sprouts was counted and their length was
measured using ImageJ (Bethesda, MA, USA).
Mouse aortic ring cultures. Aortic ring assays were performed as
described previously50 using aortas from 8- to 10-week-old C57BL/6 mice,
except that CXCL12, sHA, HYL, KM81 or IgG were added as indicated. Aortic
rings were photographed on day 10 using a Canon Power Shot S620 digital
camera connected to an Axiovert 40c Zeiss microscope and evaluated using
ImageJ.
Matrigel plug assay. Growth factor-reduced matrigel (BD Biosciences,
Heidelberg, Germany) was mixed with CXCL12 (200 ng/ml), Healon (400 mg/
ml), sHA (1 mg/ml), KM81 antibody or IgG (100 mg/ml) as indicated. Aliquots of
these mixtures (300 ml) were injected subcutaneously into both flanks of
C57Bl/6 mice. After 21 days, matrigel plugs were removed, fixed in zinc buffer
and embedded in paraffin. Paraffin sections were stained with a rat anti-
mouse CD31 antibody (0.5 mg/ml; BD Pharmingen, Heidelberg, Germany),
anti-rat Alexa Fluor 546 (Invitrogen) and DAPI (Dako).
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